Publication date: Jun 25, 2025
Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2. 30; 95% confidence interval, 2. 16-2. 45; χ, 702. 33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations.
| Concepts | Keywords |
|---|---|
| Clinicians | disease-modifying therapies |
| Fda | Multiple sclerosis |
| Increased | |
| Sclerosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Malignant melanoma |
| disease | MESH | multiple sclerosis |
Original Article
(Visited 18 times, 1 visits today)